ZIELONKA DANIEL ET AL: "Update on Huntington's disease: Advances in care and emerging therapeutic options", PARKINSONISM AND RELATED DISORDERS, vol. 21, no. 3, 19 December 2014 (2014-12-19), pages 169 - 178, XP029200000, ISSN: 1353-8020, DOI: 10.1016/J.PARKRELDIS.2014.12.013 (B8)

ANON: "Unified Huntington's Disease Rating Scale: Reliability and-Consis tenc y", MOVEMENT DISORDERS, vol. 11, no. 2, 1 January 1996 (1996-01-01), pages 136 - 142, XP055677965 (B8)

FERDINANDO SQUITIERI ET AL: "Profile of pridopidine and its potential in the treatment of Huntington disease: the evidence to date", DRUG DESIGN, DEVELOPMENT AND THERAPY, 28 October 2015 (2015-10-28), United Kingdom, pages 5827, XP055485261, ISSN: 1177-8881, DOI: 10.2147/DDDT.S65738 (B8)

GARCIA DE YEBENES JUSTO ET AL: "Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial", THE LANCET NEUROLOGY, vol. 10, no. 12, 7 November 2011 (2011-11-07), pages 1049 - 1057, XP093142840, Retrieved from the Internet <URL:https://www.sciencedirect.com/science/article/pii/S1474442211702332?via%3Dihub> DOI: 10.1016/S1474- (B8)

KIEBURTZ K D: "A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington's disease", MOVEMENT DISORDERS, vol. 28, no. 10, 28 February 2013 (2013-02-28), US, pages 1407 - 1415, XP093142858, ISSN: 0885-3185, Retrieved from the Internet <URL:https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fmds.25362> DOI: 10.1002/mds.25362 (B8)

WO-A1-2016/138130 (B8)

US-A1- 2010 167 286 (B8)

US-A1- 2014 378 508 (B8)

WO-A1-2011/107583 (B8)

WO-A1-2013/086425 (B8)

US-A1- 2006 287 299 (B8)